Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.
作者： Xia Chen , Joop van Gerven , Adam Cohen , Gabriel Jacobs
DOI: 10.1038/S41401-018-0185-5
关键词:
摘要: … anxiety disorders. However, the clinical efficacy of GABA-A α2-selective agonists for the treatment of anxiety … In addition, neurons from the BLA also activate cells in the adjacent BNST, …
chinaphar.com
nature.com参考文章(126)
Xia Chen, Sanne de Haas, Marieke de Kam, Joop van Gerven, An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists Advances in Pharmacological Sciences. ,vol. 2012, pp. 134523- 134523 ,(2012) , 10.1155/2012/134523
K. Domschke, P. Zwanzger, GABAergic and endocannabinoid dysfunction in anxiety - future therapeutic targets? Current Pharmaceutical Design. ,vol. 14, pp. 3508- 3517 ,(2008) , 10.2174/138161208786848784
Cristina M Del-Ben, Cesar AQ Ferreira, Tiago A Sanchez, Wolme C Alves-Neto, Vinicius G Guapo, Draulio B de Araujo, Frederico G Graeff, Effects of diazepam on BOLD activation during the processing of aversive faces Journal of Psychopharmacology. ,vol. 26, pp. 443- 451 ,(2012) , 10.1177/0269881110389092
David S. Baldwin, Stuart A. Montgomery, Rico Nil, Malcolm Lader, Discontinuation symptoms in depression and anxiety disorders The International Journal of Neuropsychopharmacology. ,vol. 10, pp. 73- 84 ,(2007) , 10.1017/S1461145705006358
Erwin Sigel, Benjamin P. Luscher, A closer look at the high affinity benzodiazepine binding site on GABAA receptors. Current Topics in Medicinal Chemistry. ,vol. 11, pp. 241- 246 ,(2011) , 10.2174/156802611794863562
G. Munro, J. A. Lopez-Garcia, I. Rivera-Arconada, H. K. Erichsen, E. Ø. Nielsen, J. S. Larsen, P. K. Ahring, N. R. Mirza, Comparison of the Novel Subtype-Selective GABAA Receptor-Positive Allosteric Modulator NS11394 [3′-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with Diazepam, Zolpidem, Bretazenil, and Gaboxadol in Rat Models of Inflammatory and Neuropathic Pain Journal of Pharmacology and Experimental Therapeutics. ,vol. 327, pp. 969- 981 ,(2008) , 10.1124/JPET.108.144568
J. K. Rowlett, D. M. Platt, S. Lelas, J. R. Atack, G. R. Dawson, Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 915- 920 ,(2005) , 10.1073/PNAS.0405621102
B Luscher, Q Shen, N Sahir, The GABAergic deficit hypothesis of major depressive disorder Molecular Psychiatry. ,vol. 16, pp. 383- 406 ,(2011) , 10.1038/MP.2010.120
Paul Morgan, Piet H. Van Der Graaf, John Arrowsmith, Doug E. Feltner, Kira S. Drummond, Craig D. Wegner, Steve D.A. Street, Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discovery Today. ,vol. 17, pp. 419- 424 ,(2012) , 10.1016/J.DRUDIS.2011.12.020
Hanns Möhler, The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. ,vol. 62, pp. 42- 53 ,(2012) , 10.1016/J.NEUROPHARM.2011.08.040